Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

M. S. Soloway, S. W. Hardeman, D. Hickey, J. Raymond, B. Todd, S. Soloway, M. Moinuddin

Research output: Contribution to journalArticle

486 Citations (Scopus)

Abstract

Most patients with metastatic prostate cancer will have metastasis to bone. Such patients are best monitored by serial radionuclide bone scans. One hundred sixty six men with bone metastasis from prostate cancer who received androgen deprivation therapy had their pretreatment bone scans reviewed using a semiquantitative grading system based upon the extent of disease (EOD) observed on the scan. The EOD on the scan correlated with survival. The 2-year survival rates for EOD I to IV were 94%, 74%, 68%, and 40%, respectively. The survival of patients in categories EOD I and IV significantly differed from the other categories. Men with metastatic prostate cancer entered into trials designed to evaluate the impact of treatment on survival should be stratified based upon the EOD on the bone scan. This analysis also indicates that patients in the EOD IV category have a particularly poor prognosis and may be candidates for alternative treatments.

Original languageEnglish
Pages (from-to)195-202
Number of pages8
JournalCancer
Volume61
Issue number1
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Bone and Bones
Survival
Neoplasm Metastasis
Bone Diseases
Radioisotopes
Androgens
Therapeutics
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Soloway, M. S., Hardeman, S. W., Hickey, D., Raymond, J., Todd, B., Soloway, S., & Moinuddin, M. (1988). Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer, 61(1), 195-202.

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. / Soloway, M. S.; Hardeman, S. W.; Hickey, D.; Raymond, J.; Todd, B.; Soloway, S.; Moinuddin, M.

In: Cancer, Vol. 61, No. 1, 01.01.1988, p. 195-202.

Research output: Contribution to journalArticle

Soloway, MS, Hardeman, SW, Hickey, D, Raymond, J, Todd, B, Soloway, S & Moinuddin, M 1988, 'Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan', Cancer, vol. 61, no. 1, pp. 195-202.
Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988 Jan 1;61(1):195-202.
Soloway, M. S. ; Hardeman, S. W. ; Hickey, D. ; Raymond, J. ; Todd, B. ; Soloway, S. ; Moinuddin, M. / Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. In: Cancer. 1988 ; Vol. 61, No. 1. pp. 195-202.
@article{38e79caa4508477f88389e684f9af62e,
title = "Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan",
abstract = "Most patients with metastatic prostate cancer will have metastasis to bone. Such patients are best monitored by serial radionuclide bone scans. One hundred sixty six men with bone metastasis from prostate cancer who received androgen deprivation therapy had their pretreatment bone scans reviewed using a semiquantitative grading system based upon the extent of disease (EOD) observed on the scan. The EOD on the scan correlated with survival. The 2-year survival rates for EOD I to IV were 94{\%}, 74{\%}, 68{\%}, and 40{\%}, respectively. The survival of patients in categories EOD I and IV significantly differed from the other categories. Men with metastatic prostate cancer entered into trials designed to evaluate the impact of treatment on survival should be stratified based upon the EOD on the bone scan. This analysis also indicates that patients in the EOD IV category have a particularly poor prognosis and may be candidates for alternative treatments.",
author = "Soloway, {M. S.} and Hardeman, {S. W.} and D. Hickey and J. Raymond and B. Todd and S. Soloway and M. Moinuddin",
year = "1988",
month = "1",
day = "1",
language = "English",
volume = "61",
pages = "195--202",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

AU - Soloway, M. S.

AU - Hardeman, S. W.

AU - Hickey, D.

AU - Raymond, J.

AU - Todd, B.

AU - Soloway, S.

AU - Moinuddin, M.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Most patients with metastatic prostate cancer will have metastasis to bone. Such patients are best monitored by serial radionuclide bone scans. One hundred sixty six men with bone metastasis from prostate cancer who received androgen deprivation therapy had their pretreatment bone scans reviewed using a semiquantitative grading system based upon the extent of disease (EOD) observed on the scan. The EOD on the scan correlated with survival. The 2-year survival rates for EOD I to IV were 94%, 74%, 68%, and 40%, respectively. The survival of patients in categories EOD I and IV significantly differed from the other categories. Men with metastatic prostate cancer entered into trials designed to evaluate the impact of treatment on survival should be stratified based upon the EOD on the bone scan. This analysis also indicates that patients in the EOD IV category have a particularly poor prognosis and may be candidates for alternative treatments.

AB - Most patients with metastatic prostate cancer will have metastasis to bone. Such patients are best monitored by serial radionuclide bone scans. One hundred sixty six men with bone metastasis from prostate cancer who received androgen deprivation therapy had their pretreatment bone scans reviewed using a semiquantitative grading system based upon the extent of disease (EOD) observed on the scan. The EOD on the scan correlated with survival. The 2-year survival rates for EOD I to IV were 94%, 74%, 68%, and 40%, respectively. The survival of patients in categories EOD I and IV significantly differed from the other categories. Men with metastatic prostate cancer entered into trials designed to evaluate the impact of treatment on survival should be stratified based upon the EOD on the bone scan. This analysis also indicates that patients in the EOD IV category have a particularly poor prognosis and may be candidates for alternative treatments.

UR - http://www.scopus.com/inward/record.url?scp=0023834161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023834161&partnerID=8YFLogxK

M3 - Article

C2 - 3334948

AN - SCOPUS:0023834161

VL - 61

SP - 195

EP - 202

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -